Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BI 655088
- Development stage
- Phase 1
- Lead developer
- Boehringer Ingelheim
- Modality
- Recombinant Proteins and Enzymes, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
BI 655088 is a potent and highly selective biotherapeutic antagonist of the chemokine receptor CX3CR1 (C-X3-C motif chemokine receptor 1). It is a VHH antibody (Nanobody) engineered to block CX3CR1, thereby reducing inflammation in atherosclerotic plaques. Preclinical studies demonstrated that therapeutic dosing of BI 655088 significantly inhibits plaque progression in mouse models of atherosclerosis. The drug was developed as an innovative approach to reduce inflammation and potentially decrease atherothrombotic events in patients with existing cardiovascular disease when added to standard treatments such as statins. Additionally, it has been investigated for chronic kidney disease and renal failure[1][2][6][7].
- Other names
- BI655088BI-655088BI 655088Anti-CX3CR1 NanobodyAnti-CX-3CR1 NanobodyAnti-CX 3CR1 Nanobody
02
Targets
CX3CR1 (C-X3-C motif chemokine receptor 1)
Beyond the preview
Go deeper on BI 655088.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BI 655088.